Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000. While the interim positive outcome is based on a 20-patient group, it expects to complete the phase 2 trial with 80 patients by the end of the first quarter of 2023.

Is the Pain Over for Baudax Bio Investors after a 70% Spike?

What caused Baudax Bio (NASDAQ: BXRX ) stock to double earlier today? The catalyst was undoubtedly this morning's announcement concerning a Phase 2 clinical trial of Baudax Bio's novel product, BX1000.

Why Is Baudax Bio (BXRX) Stock Up 50% Today?

Use these penny stocks risk management tips for trading The post Penny Stocks Risk Management: 3 Tips and Tricks  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks Risk Management: 3 Tips and Tricks

With a contentious time in 2022 coming to a close, it may be helpful to look back and consider the most sold-off stocks last year. Similar to learning from prior mistakes, investors may be able to garner lessons from the worst-hit market ideas.

The 7 Most Sold-Off Stocks of 2022

Baudax Bio (NASDAQ: BXRX ) stock is rocketing higher on Friday after the pharmaceutical company initiated a Phase 2 clinical trial of BX1000. BX1000 is the company's drug candidate for neuromuscular blockade in patients undergoing elective surgery.

Why Is Baudax Bio (BXRX) Stock Up 46% Today?

Baudax Bio, Inc. (BXRX) delivered earnings and revenue surprises of -366.04% and 75.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Baudax Bio, Inc. (BXRX) Reports Q3 Loss, Lags Revenue Estimates

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.